Positions

Investigator On

  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation 2019 - 2024
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by Janssen 2018 - 2023
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Private Grant  awarded by BLUEBIRD BIO INC. 2019 - 2021
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC. 2013 - 2018
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2014 - 2018
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS 2014 - 2018
  • Private Grant  awarded by ARRAY BIOPHARMA 2015 - 2016
  • Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen  awarded by University of Michigan 2012 - 2016
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University 2014 - 2015
  • Education And Training

  • Atlanta Medical Center, Internship 1999
  • Atlanta Medical Center, Residency 2001
  • UAB Hospital, Postdoctoral Fellowship 2009
  • University of Virginia Hospital, Postdoctoral Fellowship 2008
  • Full Name

  • Racquel Innis-Shelton